Abstract:Aldose Reductase (AR) reduces a variety of substrates, such as aldehydes, aldoses and corticosteroids. It is the first and rate-limiting enzyme of the polyol pathway and is an important target enzyme for diabetes-associated complications, including retinopathy, neuropathy, and nephropathy. Inhibitors targeting this enzyme are structurally different and some of them have side effects. In existing publications, computational techniques are applied to investigate the binding affinities of existing inhibitors and predicting the affinities of newly designed ligands. However, these calculations only employ coarse and approximated methods such as docking and MM/PBSA. Brute force simulations are employed to study the dynamics of the system but no converged statistics is obtained. As a result, these computations provide results not consistent with experimental values and large discrepancies exist. In the current work, we employ the enhanced sampling technique of alchemical free energy simulation to calculate the binding affinities of several ligands targeting AR. The statistical error is defined with care and the correlation in the time-series data is fully considered. The statistically optimal estimators are used to extract the free energy estimates and the predicted results are in agreement with the experimental values. Less computationally demanding end-point free energy methods are also performed to compare their efficiency with the alchemical methods. As is expected, the end-point methods are of less accuracy and reliability compared with the alchemical free energy methods. The decomposition of the free energy difference in each alchemical transformation into the enthalpic and entropic components gives further insights on the thermodynamics. The enthalpy-entropy compensation is observed in this case. As the structural data obtained from experiments are only snapshots and more details are needed to understand the dynamics of the protein-ligand system, the conformational ensemble is analyzed. We identify important residues involved in the protein-ligand binding case and short-lived interactions formed due to fluctuations in the conformational ensemble. The current work shed light on the atomic detailed understanding of the dynamics of AR-inhibitors interactions.

Calculation of PARP1-ligand Binding Free Energy Using Alanine Scanning and Interaction Entropy Method

Potential Biomarkers Of Poly (Adp-Ribose) Polymerase Inhibitors For Cancer Therapy

Human PARP1 Substrates and Regulators of Its Catalytic Activity: an Updated Overview.

Unraveling the allosteric inhibition mechanism of PARP-1 CAT and the D766/770A mutation effects via Gaussian accelerated molecular dynamics and Markov state model

Predicted Par1 Inhibitors from Multiple Computational Methods

Deciphering the Functional Mechanism of Zinc Ions of PARP1 Binding with Single Strand Breaks and Double Strand Breaks.

PARP1: A Promising Target for the Development of PARP1-based Candidates for Anticancer Intervention

How ligands regulate the binding of PARP1 with DNA: Deciphering the mechanism at the molecular level

Molecular Mechanism of Selective Binding of NMS-P118 to PARP-1 and PARP-2: A Computational Perspective.

Systematic comparison of ligand-based and structure-based virtual screening methods on poly (ADP-ribose) polymerase-1 inhibitors

Molecular modeling studies on benzimidazole carboxamide derivatives as PARP-1 inhibitors using 3D-QSAR and docking.

Interaction Entropy for Computational Alanine Scanning in Protein–protein Binding

Computational Alanine Scanning with Interaction Entropy for Protein-ligand Binding Free Energies.

Calculation of Relative Binding Free Energy for Mutations in Protein Complexes: The Alchemical Path

Strategic Identification of Anti-Cancer Compounds Targeting PARP15 in DNA Repair Pathways for Enhanced Therapeutic Efficacy

Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking and Biological Evaluation for Identification of Potential Poly (Adp-Ribose) Polymerase-1 (PARP-1) Inhibitors

Understanding Aldose Reductase-Inhibitors interactions with free energy simulation

Crystal structures of the catalytic domain of human PARP15 in complex with small molecule inhibitors

In Silico Study Simulation Targeting PARP-1 and In Vitro Study Validation Using Cancer Cell Lines

Detection of PARP-1 Activity Based on Hyperbranched-Poly (Adp-Ribose) Polymers Responsive Current in Artificial Nanochannels.

Enabling Drug Discovery for the PARP Protein Family Through the Detection of Mono-Adp-ribosylation.